Mostrar el registro sencillo del ítem

dc.creatorSiachpazidou D.I., Stavrou V.T., Astara K., Pastaka C., Gogou E., Hatzoglou C., Economou N.-T., Gourgoulianis K.I.en
dc.date.accessioned2023-01-31T09:55:45Z
dc.date.available2023-01-31T09:55:45Z
dc.date.issued2020
dc.identifier.issn17350344
dc.identifier.urihttp://hdl.handle.net/11615/78950
dc.description.abstractBackground: Obstructive sleep apnea syndrome (OSAS) is a disorder with high prevalence among adults and is an independent risk factor for various diseases, especially those affecting the central nervous system (CNS). Continuous positive airway pressure (CPAP) is usually the optimal choice of treatment for OSAS. Alzheimer’s disease (AD) is a neurodegenerative disease affecting a large proportion of the elderly population. The purpose of this study was to collect information concerning the two pathological entities and investigate the effectiveness of CPAP in the treatment of AD. Materials and Methods: In this review, Twenty articles were found concerning OSAS and AD, of which one article was about treatment with donepezil and seven articles considered treatment with CPAP. Results: Serious OSAS and short sleep duration are associated with a high risk of developing dementia. Respiratory distress during sleep is associated with developing mild cognitive impairment at younger ages. The cerebrovascular damage of AD patients is correlated with the severity of OSAS. Lower cerebrospinal fluid levels are associated with memory disturbances and oxygen saturation parameters in patients with OSAS-AD. Continuous use of CPAP is related to the delayed onset of cognitive impairment and is suggested as an effective method of protecting cognitive function, depression, sleep quality and architecture, and daytime sleepiness in AD patients with good compliance. Treatment of CPAP patients with OSAS-AD is suggested as an effective method of protecting cognitive function. Conclusion: Clinicians dealing with AD patients should consider CPAP treatment when OSAS coexists. © 2020 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran.en
dc.language.isoenen
dc.sourceTanaffosen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85114820404&partnerID=40&md5=7155d77c4ec78c091b2e50883b7e9738
dc.subjectalpha tocopherolen
dc.subjectamyloid beta proteinen
dc.subjectapolipoprotein Een
dc.subjectascorbic aciden
dc.subjectbiological markeren
dc.subjectdonepezilen
dc.subjectseleniumen
dc.subjecttau proteinen
dc.subjecttrazodoneen
dc.subjectadenotonsillectomyen
dc.subjectAlzheimer diseaseen
dc.subjectapnea hypopnea indexen
dc.subjectblood brain barrieren
dc.subjectblood oxygenationen
dc.subjectcentral nervous systemen
dc.subjectcerebrospinal fluiden
dc.subjectcerebrovascular diseaseen
dc.subjectcognitionen
dc.subjectcognitive defecten
dc.subjectcontinuous positive airway pressureen
dc.subjectdaytime somnolenceen
dc.subjectdegenerative diseaseen
dc.subjectdementiaen
dc.subjectdepressionen
dc.subjectdisease severityen
dc.subjectexcessive daytime sleepinessen
dc.subjectfatigueen
dc.subjecthumanen
dc.subjectneuropsychological testen
dc.subjectnuclear magnetic resonance imagingen
dc.subjectoxygen saturationen
dc.subjectREM sleepen
dc.subjectrespiratory distressen
dc.subjectReviewen
dc.subjectrisk factoren
dc.subjectsleep disorderen
dc.subjectsleep disordered breathingen
dc.subjectsleep qualityen
dc.subjectsleep timeen
dc.subjectuvulopalatopharyngoplastyen
dc.subjectShaheed Beheshti University of Medical Sciences and Health Servicesen
dc.titleAlzheimer’s disease in patients with obstructive sleep apnea syndromeen
dc.typeotheren


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem